Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07760012
Recruiting Not applicable

68Ga-SorB PET/CT Imaging in Patients With Solid Tumors

NCT07760012 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Not applicable
Started
2026-08-13
Last updated
2026-10-15

Condition(s) studied

Melanoma (Skin Cancer)Hepatocellular CarcinomaLung CancerBreast CancerPancreatic CancerOvarian CancerCholangiocarcinoma

Investigational drug(s) / intervention(s)

68Ga-SorB PET/CT

68Ga-SorB PET/CT: Participants will receive a single intravenous administration of 68Ga-SorB (approximately 3.7 MBq/kg), followed by whole-body PET/CT imaging approximately 60 minutes after injection. The imaging findings will be compared with clinically indicated 18F-FDG PET/CT and reference standard findings to evaluate the safety, feasibility, biodistribution, tumor uptake, and exploratory diagnostic performance of 68Ga-SorB PET/CT.

Study summary

This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors. Eligible participants with confirmed or suspected melanoma, hepatocellular carcinoma, lung cancer, pancreatic cancer, breast cancer, ovarian cancer, or cholangiocarcinoma will undergo 68Ga-SorB PET/CT imaging. The imaging findings will be compared with standard-of-care 18F-FDG PET/CT, using pathology results and/or clinical follow-up as the reference standard.

The primary objectives are to evaluate the safety and tolerability of 68Ga-SorB, assess imaging feasibility, and characterize tumor uptake using quantitative PET parameters, including SUVmax and tumor-to-background ratio (TBR). Secondary exploratory objectives include comparing lesion detection between 68Ga-SorB PET/CT and 18F-FDG PET/CT, assessing diagnostic sensitivity and specificity, evaluating imaging characteristics across different tumor types, and exploring the correlation between Sortilin expression and tracer uptake. This study will provide preliminary clinical evidence supporting the development of Sortilin-targeted molecular imaging and future theranostic applications.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 or older. * Histologically confirmed or clinically suspected melanoma, hepatocellular carcinoma, lung cancer, breast cancer, pancreatic cancer, ovarian cancer, or cholangiocarcinoma. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate hematologic, hepatic, renal, and coagulation function: * White blood cell count ≥ 4.0 × 10\^9/L or absolute neutrophil count ≥ 1.5 × 10\^9/L; * Platelet count ≥ 100 × 10\^9/L; * Hemoglobin ≥ 90 g/L; * PT or APTT ≤ 1.5 × upper limit of normal (ULN); * Total bilirubin ≤ 1.5 × ULN; * ALT and AST ≤ 2.5 × ULN (or ≤ 5 × ULN for participants with liver metastases); * ALP ≤ 2.5 × ULN (or ≤ 4.5 × ULN for participants with bone or liver metastases); * Blood urea nitrogen and serum creatinine ≤ 1.5 × ULN. * Normal cardiac function. * Estimated life expectancy of at least 12 weeks. * Willing and able to comply with study procedures and follow-up. * At least one measurable target lesion according to RECIST version 1.1. * Participants of childbearing potential agree to use effective contraception during the study and for 3 months after PET/CT imaging. * Clinically indicated to undergo 18F-FDG PET/CT for tumor evaluation. * Able to understand the study procedures and provide written informed consent. Exclusion Criteria: * Pregnant or breastfeeding women. * Severe dysfunction of major organs (including heart, liver, or kidney) that, in the investigator's judgment, would make participation inappropriate. * Inability to tolerate PET/CT imaging or complete study follow-up. * Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Primary outcome measure(s)

  • Incidence of adverse events related to 68Ga-SorB PET/CT — From tracer administration until completion of the imaging visit (approximately 24 hours).
    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) related to administration of 68Ga-SorB, graded according to CTCAE.
  • Successful completion of 68Ga-SorB PET/CT imaging — At completion of PET/CT imaging (approximately 60 minutes after tracer injection)
    Proportion of participants completing 68Ga-SorB PET/CT with evaluable image quality.
  • Tumor uptake of 68Ga-SorB measured by SUVmax — At PET/CT imaging (approximately 60 minutes after tracer injection)
    Maximum standardized uptake value (SUVmax) of target lesions measured on 68Ga-SorB PET/CT.

Trial sites (1)

FacilityCityRegionStatus
Peking University Third Hospital Beijing Beijing Municipality Recruiting

More Peking University Third Hospital trials in China

Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease Recruiting
A Study on Diagnosis and Treatment Strategies for Atlantoaxial Dislocation Recruiting
LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer Enrolling by invitation
Prospective Cohort Study on Refractory Rheumatoid Arthritis Recruiting
Multi-Agent Collaborative ADR Prediction With Human-Machine Decision Comparison Recruiting

Other trials for the same condition

Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3 Recruiting
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma Recruiting
CAR-NK Cells (CL-NK-001) in Pancreatic Cancer Recruiting
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure Recruiting
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07760012 on ClinicalTrials.gov ↗ ← All trials in China